Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma.

MLA

Xuesong Yao, et al. “Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination with Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma.” Molecular & Clinical Oncology, vol. 3, no. 4, July 2015, pp. 189–95. EBSCOhost, https://doi.org/10.3892/mco.2015.554.

APA

Xuesong Yao, Dong Yan, Dezhong Liu, Huiying Zeng, & Huai Li. (2015). Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Molecular & Clinical Oncology, 3(4), 189–195. https://doi.org/10.3892/mco.2015.554

Chicago

Xuesong Yao, Dong Yan, Dezhong Liu, Huiying Zeng, and Huai Li. 2015. “Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination with Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma.” Molecular & Clinical Oncology 3 (4): 189–95. doi:10.3892/mco.2015.554.